ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR)
CUSIP: 04280A100
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 135,488,140
- Total 13F shares
- 110,897,224
- Share change
- +5,233,340
- Total reported value
- $3,823,917,269
- Put/Call ratio
- 27%
- Price per share
- $34.49
- Number of holders
- 300
- Value change
- +$261,693,126
- Number of buys
- 164
- Number of sells
- 121
Quarterly Holders Quick Answers
What is CUSIP 04280A100?
CUSIP 04280A100 identifies ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04280A100:
Top shareholders of ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
14%
|
19,424,887
|
$306,913,213 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
11%
|
15,525,072
|
$245,296,137 | — | 30 Jun 2025 | |
| Avoro Capital Advisors LLC |
13D/G
13F
|
Company |
8.3%
|
11,517,441
|
$193,377,834 | -$8,581,554 | 30 Jun 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
4.6%
|
6,371,056
|
$106,970,030 | -$10,547,360 | 30 Jun 2025 | |
| Slate Path Capital LP |
13F
|
Company |
3.9%
|
5,232,000
|
$82,665,600 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
3.8%
|
5,170,310
|
$81,690,906 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
2,978,505
|
$47,066,861 | — | 30 Jun 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
2%
|
2,684,317
|
$42,412,208 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2%
|
2,669,880
|
$42,184,104 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.6%
|
2,155,998
|
$34,064,769 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.6%
|
2,115,314
|
$33,421,961 | — | 30 Jun 2025 | |
| NORGES BANK |
13F
|
Company |
1.4%
|
1,924,957
|
$30,414,321 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.3%
|
1,705,266
|
$26,943,214 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
1.2%
|
1,600,596
|
$25,289,416 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.94%
|
1,272,066
|
$20,098,642 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.86%
|
1,170,745
|
$18,497,771 | — | 30 Jun 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.71%
|
960,245
|
$15,171,871 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.69%
|
939,174
|
$14,838,949 | — | 30 Jun 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.61%
|
822,343
|
$12,994,000 | — | 30 Jun 2025 | |
| Western Financial Corp/CA |
13F
|
Company |
0.61%
|
820,239
|
$12,959,776 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.6%
|
818,079
|
$12,925,654 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.56%
|
762,665
|
$12,050,107 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.55%
|
746,156
|
$11,789,265 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.46%
|
624,496
|
$9,867,036 | — | 30 Jun 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.45%
|
612,214
|
$9,850,523 | — | 30 Jun 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.46%
|
623,097
|
$9,844,933 | — | 30 Jun 2025 | |
| Kenneth Allen Myszkowski |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
455,433
|
$8,967,476 | — | 04 Jan 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.37%
|
503,654
|
$7,957,733 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.36%
|
482,055
|
$7,616,466 | — | 30 Jun 2025 | |
| Javier San Martin |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
198,497
|
$7,417,833 | — | 04 Jan 2024 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.33%
|
451,655
|
$7,136,147 | — | 30 Jun 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.32%
|
428,386
|
$6,768,499 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.3%
|
409,603
|
$6,471,727 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.3%
|
407,644
|
$6,440,775 | — | 30 Jun 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.3%
|
407,341
|
$6,435,987 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.3%
|
400,210
|
$6,323,000 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.29%
|
391,800
|
$6,190,440 | — | 30 Jun 2025 | |
| Clearbridge Investments, LLC |
13F
|
Company |
0.28%
|
380,886
|
$6,018,004 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.27%
|
366,711
|
$5,794,034 | — | 30 Jun 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.27%
|
359,997
|
$5,687,931 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.23%
|
310,354
|
$4,903,593 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.23%
|
307,745
|
$4,862,371 | — | 30 Jun 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.2%
|
277,333
|
$4,454,723 | — | 30 Jun 2025 | |
| SILVERCREST ASSET MANAGEMENT GROUP LLC |
13F
|
Company |
0.21%
|
280,177
|
$4,426,797 | — | 30 Jun 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.2%
|
267,027
|
$4,219,027 | — | 30 Jun 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.19%
|
260,000
|
$4,108,000 | — | 30 Jun 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.18%
|
247,598
|
$3,981,376 | — | 30 Jun 2025 | |
| James Hassard |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
105,750
|
$3,951,878 | — | 22 Jun 2021 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.17%
|
235,446
|
$3,720,047 | — | 30 Jun 2025 | |
| CAPITAL FUND MANAGEMENT S.A. |
13F
|
Company |
0.17%
|
226,365
|
$3,576,567 | — | 30 Jun 2025 |
Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) as of Q3 2025
As of 30 Sep 2025,
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) was held by
300 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
110,897,224 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, STATE STREET CORP, FMR LLC, Slate Path Capital LP, GEODE CAPITAL MANAGEMENT, LLC, Siren, L.L.C., Driehaus Capital Management LLC, and ARROWSTREET CAPITAL, LIMITED PARTNERSHIP.
This page lists
300
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
279
Q3 2025 holders
300
Holder diff
21
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.